Sign in

CIK 0001677077

  • Emerging growth company

Alzamend Neuro, Inc.

Sign in to watch
Ticker
ALZN
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
FY end
Apr 30
Incorporated
DE
Entity type
Operating
EIN
811822909
Phone
+1 844-722-6333
Business address
480 PEACHTREE ROAD NE, SECOND FLOOR, SUITE 103, ATLANTA, GA, 30326
  1. 4 Open-market buy Director bought 1,000 shares at $0.69 ($688)
  2. 4 Open-market buy Director bought 334 shares at $0.91 ($304)
  3. 4 Open-market buy Director bought 2,000 shares at $1.06 ($2,127)
  4. 4 Derivatives Options or other derivatives
  5. 4 Derivatives Options or other derivatives
  6. 4 Other disposition Director disposed of 661,168 shares (other)
  7. 4 Open-market buy Director bought 5,000 shares at $1.02 ($5,093)
  8. 4 Open-market buy 10% owner bought 700 shares at an average $0.91 ($635)
  9. 4 Open-market buy Chief Financial Officer bought 53,000 shares at $0.19 ($10,234)
  10. 4 Open-market buy 10% owner bought 18,000 shares at $0.59 ($10,705)
  11. 4 Open-market buy Chief Executive Officer bought 37,000 shares at $0.54 ($19,999)
  12. 4 Open-market buy Director bought 10,000 shares at $0.44 ($4,350)
  13. 4 Open-market buy 10% owner bought 9,000 shares at an average $0.46 ($4,155)
  14. 4 Option exercise Director acquired 500,000 shares (option exercise)
  15. 4 Open-market buy 10% owner bought 1,000 shares at $0.60 ($597)
  16. 4 Open-market buy 10% owner bought 4,000 shares at an average $0.57 ($2,277)
  17. 4 Open-market buy 10% owner bought 5,000 shares at $0.81 ($4,050)
  18. 4 Open-market buy 10% owner bought 43,000 shares at an average $0.86 ($36,773)
  19. 4 Insider Changes in Ownership
  20. 4 Insider Changes in Ownership

Page 3 of 9 · 170 filings